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SUMMARY
DNA methylation at the C-5 position of cytosine (5mC) regulates gene expression and plays 
pivotal roles in various biological processes. The TET dioxygenases iterative oxidation of 5mC, 
leading to eventual demethylation intermediate. Inactivation of TET enzymes causes multi-stage 
developmental defects, impaired cell reprogramming and hematopoietic malignancies. However, 
little is known about how TET activity is regulated. Here we show that all three TET proteins bind 
to VprBP and are monoubiquitylated by the VprBP-DDB1-CUL4-ROC1 E3 ubiquitin ligase 
(CRL4VprBP) on a highly conserved lysine residue. Deletion of VprBP in oocytes abrogated 
paternal DNA hydroxymethylation in zygotes. VprBP-mediated monoubiquitylation promotes 
TET binding to chromatin. Multiple recurrent TET2-inactivating mutations derived from leukemia 
target either the monoubiquitylation site (K1299) or residues essential for VprBP binding. 
Cumulatively, our data demonstrate that CRL4VprBP is a critical regulator of TET dioxygenases 
during development and in tumor suppression.
INTRODUCTION
5-methylcytosine (5mC) is a genomic modification that negatively regulates gene expression 
and is essential for diverse biological processes (Li, 2002; Wu and Zhang, 2014). 5mC 
patterning is established by DNA methyltransferase (DNMT) 3 and is maintained by 
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DNMT1, which methylates newly replicated DNA (Goll and Bestor, 2005). Once 
considered irreversible, the recent identification of the TET family of proteins (TET1, 2 and 
3 in mammalian cells) has changed our view of 5mC stability (Tahiliani et al., 2009). TET 
proteins are α-ketoglutarate (α-KG)- and Fe(II)-dependent dioxygenases that catalyze three 
steps of iterative oxidation, first converting 5mC to 5-hydroxymethyl cytosine (5hmC), then 
5hmC to 5-formyl cytosine (5fC), and finally 5fC to 5-carboxy cytosine (5caC). 5caC can be 
removed by DNA glycosylase TDG, resulting in 5-unmodified cytosine (He et al., 2011; Ito 
et al., 2011). Besides being an intermediate in demethylation, emerging data indicate that 
5hmC is recognized by several chromatin factors and may directly contribute to gene 
regulation (Mellen et al., 2012; Yildirim et al., 2011).
Conditional zygotic deletion of Tet3 blocks paternal-genome conversion of 5mC into 5hmC 
and results in multiple developmental defects, supporting a critical developmental role for 
TET enzymes (Gu et al., 2011). Tet1 depletion results in defective DNA demethylation in 
primordial germ cells and decreased expression of a subset of meiotic genes, leading to 
reduced female germ cells and fertility (Yamaguchi et al., 2012). During induced pluripotent 
stem cell (iPSC) reprogramming, TET1 and TET2 promote 5mC-to-5hmC conversion to 
facilitate imprint erasure and establish pluripotency in somatic cells (Costa et al., 2013; 
Doege et al., 2012; Piccolo et al., 2013). Pathologically, the TET2 gene is frequently 
mutated in human hematopoietic malignancies of both myeloid, in particular acute myeloid 
leukemia (AML, ~15–20%), and lymphoid lineages, such as angioimmunoblastic T-cell 
lymphoma (AITL, ~30–40%) (Delhommeau et al., 2009; Quivoron et al., 2011; Tefferi et 
al., 2009). While the biological function and catalytic mechanism of TET enzymes are 
extensively investigated, little is known about their regulation.
The covalent attachment of ubiquitin to a substrate protein (ubiquitylation) is involved in 
most cellular processes (Glickman and Ciechanover, 2002). Ubiquitylation proceeds through 
sequential reactions promoted by a ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2), and finally a ubiquitin ligase (E3) that binds substrates and 
determines specificity. Substrate modification with either a single ubiquitin or various 
lengths and linkages of ubiquitin chains enables substrate recognition by distinct ubiquitin-
binding proteins, leading to specific biochemical consequences including degradation, 
translocation, and recruitment of other proteins. Cullin proteins, which comprise the largest 
family of E3s, form multiple cullin-ring ubiquitin ligase (CRLs) complexes that include a 
small RING protein, ROC1 or ROC2 (also known as RBX), which activates E2, and 
substrate recognition subunits. CUL4, conserved from yeast to humans, has two paralogs in 
mammalian cells, CUL4A and CUL4B. Both use damaged DNA binding protein 1 (DDB1) 
as a linker to interact with multiple DDB1-binding WD40 (DWD, also known as DCAF for 
DDB1 and cullin associated factors) proteins that serve as substrate recognition subunits. 
The functions of CUL4 genes have been genetically linked to chromatin regulation (Jackson 
and Xiong, 2009). This report shows that VprBP/DCAF1, one of the strongest and most 
abundant binding partners of DDB1 (McCall et al., 2008), promotes monoubiquitylation of 
TET enzymes and their DNA binding.
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VprBP binds the cysteine-rich, dioxygenase (CD) domain of TET
The C-terminal WD40 domain of VprBP binds to DDB1 and, through DDB1, interacts with 
CUL4 to assemble an active catalytic moiety while the N-terminal region is predicted to 
interact with substrates (McCall et al., 2008; Nakagawa et al., 2013). Thus, we established 
293T cells stably expressing a FLAG-tagged VprBP deletion mutant that contains the N-
terminal 909 amino acids (VprBPN909). We conducted an immunoprecipitation (IP) 
followed by mass spectrometric (IP-Mass spec) analysis in this cell line to identify proteins 
that specifically bind to the VprBPN909 mutant (Figure 1A). The VprBPN909 mutant does 
not contain the DDB1 binding domain, thus the association with CUL4 and the catalytic 
ROC1 RING finger subunit is disrupted, potentially trapping the binding of VprBP with its 
substrates. We identified a large number of potential VprBP-interacting proteins, including 
TET2 (Figure S1 and Table S1). Immunoblotting confirmed the retention of VprBPN909 in 
TET2 immunoprecipitates and also demonstrated that full-length VprBP binds to TET2 
(Figures 1A and 1E). To determine the VprBP binding region in TET2, we constructed 
several deletion mutants and found the C-terminal cysteine-rich dioxygenase (CD) domain 
of TET2 (CD2) to be primarily responsible for binding to VprBP (Figure 1B). Consistent 
with the high conservation of CD domains among TET paralogs, all three TET CD domains 
and full length TET proteins bound to VprBP in cells (Figures 1C and 1D). Catalytically 
inactive TET CDs also bound to VprBP (Figure 1C), suggesting that the catalytic activity is 
not involved in this binding. Importantly, endogenous TET proteins were readily detected in 
association with endogenous VprBP in mouse embryonic fibroblasts (MEFs), mouse 
embryonic stem (ES) cells and human monocytes (Figure 1E). An in vitro binding assay 
showed that VprBP, but not DDB1, directly binds to TET2-CD (Figure 1F). Together, these 
studies demonstrated that VprBP binds directly to all three TET proteins.
VprBP function is important for paternal DNA hydroxymethylation and zygotic 
development
To determine the functional significance of VprBP-TET interaction, the effect of VprBP 
deletion on 5hmC level in MEF cells was examined. Because Vprbp is essential for mouse 
embryo development and cell growth, we used a conditional Vprbp knockout mouse strain 
we previously created (McCall et al., 2008)-VprBPf. Here, expression of cre recombinase 
deletes a 2,358 bp genomic segment containing exons 7 and 8, which encodes 203 amino 
acid residues (residue Val172 to Ala374). VprBPf/f MEFs were infected with adenovirus-
expressing Cre to effectively delete VprBP gene and abolish the expression of VprBP 
mRNA, but not affecting the expression of either Tet2 or Tet3 (Figure 2A). Deletion of 
VprBP gene caused substantial reduction of 5hmC, suggesting that the function of VprBP is 
important for TET activity (Figure 2A).
One critical function of TET family dioxygenases is TET3-catalyzed paternal genome 
hydroxymethylation in the zygote (Gu et al., 2011). To determine the physiological 
significance of CRL4VprBP-mediated TET activation, we next examined the role of VprBP 
in paternal genome DNA hydroxymethylation and zygotic development. Vprbpf/f were 
crossed with Zp3-Cre mice expressing the cre recombinase under the promoter of mouse 
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zona pellucida 3 gene (Zp3). This cross led to Vprbp knockout exclusively in the growing 
oocyte, prior to completion of the first meiotic division (Lewandoski et al., 1997). To 
determine the effects of oocyte Vprbp deletion on zygotic development, female Vprbpf/f and 
Vprbpf/f;Zp3-Cre mice were superovulated, and embryos were examined microscopically. 
While the Vprbpf/f embryos developed to the 4-cell stage, the Vprbpf/f;Zp3-Cre zygotes were 
arrested at the 1-cell stage and failed to start embryogenesis or cleavage (Figure 2B) which 
reveals a critical function of VprBP in zygotic development. Synchronously, VprBP was 
expressed at a readily detectable level in oocytes with an evident accumulation in the 
nucleus (Figure 2C). Efficient deletion of VprBP by Zp3-driven Cre was confirmed by 
immunohistochemistry (Figure 2C). This analysis showed a reproducible and partially 
penetrant developmental defect in a fraction of oocytes (Figure 2C and Figure S2). Notably, 
deletion of VprBP in zygotes resulted in markedly reduced TET3 protein (Figure 2D) and a 
concomitant loss of paternal DNA hydroxymethylation (Figure 2E). Deletion of VprBP did 
not affect Tet3 mRNA level (Figure 2F). These data demonstrate a critical function of 
VprBP in maintaining the level of Tet3 protein and supporting the activity of Tet enzymes 
during zygotic development. Zygotic deletion of Tet3 in mice, while abolishing 5mC to 
5hmC conversion in the male pronucleus, did not significantly affect early zygotic 
development (Gu et al., 2011; Wossidlo et al., 2011), suggesting that developmental defects 
observed in VprBP-deficient zygotes involve additional events independent of the defect in 
paternal chromosome demethylation. Consistent with this notion, we noticed in the VprBP-
deficient zygotes that pronuclei appeared and DNA more condensed when compared to 
controls. It is likely that VprBP may have additional substrate(s) that are important for cell 
cycle progression in zygotes.
CRL4VprBP monoubiquitylates TET proteins
To gain mechanistic insight into VprBP-TET interaction, we first carried out an in vivo 
ubiquitylation assay in cultured cells. This experiment revealed surprisingly that TET2 is 
ubiquitylated as a discrete band, which is indicative of monoubiquitylation, rather than a 
ladder of high-molecular weight conjugates that result from polyubiquitylation (Figure 3A). 
TET2 ubiquitylation was enhanced by the overexpression of wild-type VprBP, but not either 
VprBPRARA (Figure S3A) mutant defective in DDB1 binding, VprBPN909 mutant lacking 
the DDB1-binding WD40 domain, or VprBPC590 lacking the N-terminal portion involved in 
TET2 binding (Figure 3A). To directly test the possibility that TET2 is a substrate of 
CRL4VprBP, we performed an in vivo ubiquitylation assay of TET2 in cells depleted for 
VprBP, DDB1, or a combination of CUL4A and CUL4B which revealed markedly reduced 
monoubiquitylation of TET2 after knocking down each individual CRL4 component (Figure 
3B). The decrease of TET2 monoubiquitylation by VprBP depletion was restored by ectopic 
expression of a siRNA-resistant VprBP (Figure S3B), confirming the specificity of VprBP 
knockdown on TET2 ubiquitylation. CUL4A and CUL4B, although closely related, are 
distinct in their subcellular localization. Whereas CUL4A resides predominantly in the 
cytoplasm, CUL4B localizes mostly in the nucleus (Nakagawa and Xiong, 2011). To 
determine the subcellular location of CRL4VprBP-mediated ubiquitylation of TET2, we 
knocked down CUL4A and CUL4B separately and examined TET2 ubiquitylation. 
Monoubiquitylation of TET2 was substantially reduced to a similar level by the depletion of 
either CUL4 gene and nearly completely abolished by the combined knock down of both 
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CUL4 genes (Figure 3C). This result suggests that TET2 can be ubiquitylated in both the 
cytoplasm and the nucleus and that both CUL4A and CUL4B participate in TET2 
monoubiquitylation. Nearly complete elimination of TET2 monoubiquitylation by combined 
CUL4A and CUL4B knock down also indicated that CRL4VprBP is the major ubiquitin 
ligase for TET2.
To determine whether TET1 and TET3 are also monoubiquitylated by CRL4A/BVprBP, we 
knocked down VprBP and examined their ubiquitylation. We found that both ectopically 
expressed TET1 and TET3 are ubiquitylated as a discrete band which was almost 
completely abolished by VprBP knockdown (Figure 3D). Conversely, we co-expressed 
VprBP with either TET1 or TET3 and found a positive correlation between VprBP level and 
ubiquitylation level of TET1 and TET3 (Figure 3E). Together, these results demonstrate that 
CRL4A/BVprBP catalyzes monoubiquitylation of all three TET proteins.
We then carried out an in vitro ubiquitylation assay of TET2 and TET3. Incubation of 
immunopurified TET2 (Figure 3F) or TET3 (Figure S3C) with E1, E2, ubiquitin, ATP and 
CRL4AVprBP E3 immunocomplex resulted in a clear, single, ubiquitylated species of TET2 
and TET3 that were not seen when either E1, E2, or E3 was omitted. In vitro incubation of 
purified TET2 (Figure 3G) or TET3 (Figure S3D) with a CRL4AVprBP immunocomplex 
containing mutant VprBP that is deficient in binding to DDB1 (VprBPRARA and 
VprBPN909) abolished the TET2 monoubiquitylation.
TET proteins are monoubiquitylated by CRL4VprBP E3 ligase at a conserved Lys residue
Unlike degradation-associated polyubiquitylation that does not generally modify a specific 
lysine residue, monoubiquitylation usually targets a specific lysine. The first attempt to 
identify the TET monoubiquitylation site by IP-mass spec analyses was not successful (data 
not shown). We then reasoned that, if CRL4VprBP-mediated TET monoubiquitylation is 
important for TET function, mutation of the ubiquitylation site in TET2 would cause loss of 
function in a disease such as AML, in which TET2 is frequently mutated. In addition to 
truncations and frameshifts by insertions or deletions, a large number of TET2 missense 
mutations (>250) have been reported in AML. Intriguingly, we found mutations of only two 
lysine residues in TET2: K1117 (Gelsi-Boyer et al., 2009; Rocquain et al., 2010) and K1299 
(Delhommeau et al., 2009; Jankowska et al., 2009; Kosmider et al., 2009). These mutations 
were reported to be mutated in two (K1117-to-R) and three (K1299-to-N and K1299-to-E) 
AML patients, respectively. K1299, but not K1117, is highly conserved among vertebrates 
as well as TET protein paralogs (Figures 4A, 4B, and Figure S4A). We recreated paralogous 
AML mutants corresponding to K1299 of human TET2 in mouse Tet2 (K1212N and 
K1212E), mouse Tet1 (K1537N and K1537E), and mouse Tet3 (K983N and K983E). Both 
K-to-N and K-to-E mutations of all three TET proteins significantly reduced their respective 
ubiquitylation, regardless of whether the CD domain (Figure 4C) or full-length TET proteins 
(Figure 4D) were assayed. We also characterized the K1299R mutant, which replaces the 
Lys with a similar positively-charged Arg. This replacement also disrupted TET2 
ubiquitylation (Figure S4B). A residual ubiquitylated TET was still seen, especially for 
TET3, when the ubiquitylation site was mutated, but its intensity was not affected by the 
overexpression of VprBP as the wild-type TET3 (Figure S4C), suggesting that this 
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conserved lysine residue is the predominant site of VprBP E3 ligase. We conclude that all 
three TET proteins are primarily monoubiquitylated by CRL4VprBP on a conserved lysine 
residues paralogous to K1299 in TET2.
To more definitively demonstrate the monoubiquitylated form of TET proteins as a discrete 
band, we considered the large size of TET proteins (2136, 2002 and 1660 residues for 
human TET1, TET2 and TET3, respectively) which might causes co-migration of both 
modified and unmodified forms. To this end, we first co-expressed a shorter CD domain of 
TET2 (Figure 1B) with VprBP to increase the monoubiquitylated fraction and resolved the 
lysate by a low percentage (7%) SDS-PAGE. A clearly separated band was seen when TET2 
(CD) was singularly expressed. The intensity of this band was 20.2% of that of the 
unmodified form and was increased to 41.7% after VprBP overexpression (Figure 4E), 
suggesting that a significant fraction of TET2 can be monoubiquitylated by VprBP. 
Furthermore, mutations of K1299 to either glutamic acid (KE), asparagine (KN) or arginine 
(KR) all eliminated this band (Figure 4F).
To examine the ubiquitylation of endogenous TET2 protein, we raised a rabbit polyclonal 
antibody using a branched human TET2 peptide as an antigen that conjugated the last three 
amino acid residues of ubiquitin (Arg-Gly-Gly) onto the K1299 residue (see Experimental 
Procedures for details). After clearing the antibody twice with excess unmodified peptides, 
we verified the specificity of the anti-UbTET2(K1299) antibody by dot-blot (Figure S4D). 
The anti-UbTET2(K1299) antibody readily detected a band in cells ectopically expressing 
wild-type TET2, but no band in cells expressing K1299N mutant TET2 (Figure 4G), 
validating monoubiquitylation at K1299. We then examined a panel of cell lines for in vivo 
TET2 ubiquitylation by resolving total cell lysates through a gradient (4-15%) SDS-PAGE 
to achieve better separation of high molecular proteins. Both the level of total TET2 protein 
and the intensity of the upper band varied significantly from cell line to cell line (Figure 
4H). Immunoblotting of the same lysates with the anti-UbTET2(K1299) antibody detected a 
single band in U2OS cells that corresponds to the upper band in size, but not in other cell 
lines that do not express the upper band (lower panel of Figure 4H), confirming the upper 
band as K1299-monoubiquitylated form of TET2. The upper band of TET2 was expressed at 
a low level in serum-starved U2OS cells and was stimulated following serum stimulation 
(Figure 4I). This pattern of the upper band matches perfectly with the band detected by the 
anti-UbTET2(K1299) antibody (middle panel of Figure 4I). Treatment of cells with PR-619, 
a non-specific inhibitor of deubiquitylase, increased both the intensity of the upper band and 
the band detected by the anti-UbTET2(K1299) antibody (Figure 4J). Together, these results 
demonstrate that TET2 is monoubiquitylated by VprBP-mediated E3 ligase at Lys1299.
VprBP-mediated monoubiquitylation promotes TET binding to DNA in vitro
In exploring the functional significance of VprBP-mediated TET monoubiquitylation, we 
examined several possibilities including the effect of monoubiquitylation on TET’s binding 
to the substrate DNA. Binding of TET proteins to DNA exhibits a preference for DNA 
containing unmodified cytosine (Ko et al., 2013; Xu et al., 2012). Both wild-type and AML-
derived K1299N (KN) and K1299E (KE) mutant TET2 proteins were expressed and 
immunuopurified from 293T cells and incubated with double-stranded DNA 
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oligonucleotides containing a single unmethylated or methylated CpG. Gel-shift assay 
showed that wild-type TET2 bound readily to the unmethylated DNA oligo, as expected. 
However, both the K1299N and K1299E mutations disrupted the binding (Figure 5A). 
Mutations targeting the monoubiquitylation site of TET1 and TET3 also disrupted their 
ability to bind DNA (Figure 5B). Co-expression of VprBP, which increases TET2 
monoubiquitylation (Figures 3A and 4E), enhanced TET2 DNA binding (Figure 5C).
We next performed sequential immunopurifications after triple transfection of cells with 
FLAG-TET2, Myc-VprBP and HA-Ub. We first used the FLAG antibody to purify the total 
TET2 protein and then the HA antibody to enrich for ubiquitylated TET2. This experiment 
demonstrated that, when similar amounts of TET2 proteins were incubated with DNA 
oligonucleotides, TET2 eluted from HA-beads was enriched for monoubiquitylation and 
bound DNA much stronger than TET2 eluted from FLAG-beads (Figure 5D). The 
quantification showed that when normalized to total (Flag-tagged) TET2, this sequential IP-
enriched ubiquitylated form of TET2 by 4.55 fold which correlates with a 4.5 fold increase 
of TET2 binding to DNA. Conversely, we performed sequential immunopurification and 
immunodepletion experiments, first using the FLAG antibody to purify total TET2 proteins 
and then the HA antibody to deplete ubiquitylated TET2. Depletion substantially removed 
monoubiquitylated TET2 and, accordingly, decreased DNA binding activity (Figure 5E), 
supporting the notion that monoubiquitylation promotes TET binding to DNA in vitro.
VprBP-mediated monoubiquitylation promotes TET binding to DNA in vivo
To corroborate the in vitro assay, the effect of VprBP-mediated monoubiquitylation on 
TET2’s binding to DNA was determined in cells. ChIP-qPCR assays on multiple, previously 
identified, TET target sites (Deplus et al., 2013) were performed which showed that wild-
type, but not K1299N or K1299E mutant TET2, bound to its target genes (Figure 6A). Co-
expression with wild-type, but not RARA or N909 mutant VprBP deficient in DDB1 
binding enhanced TET2 DNA binding (Figure 6B). These results support the critical 
importance of both K1299 and VprBP in promoting TET2 binding to DNA.
The distribution of monoubiquitylated and unmodified TET2 was then determined in cells. It 
was noted, by direct immunoblotting, that the anti-TET2 antibody predominantly detects one 
single band in the lysate prepared using a mild NP-40 (0.5%) lysis buffer which does not 
solubilize chromatin-bound proteins. Two clear bands appeared from lysate prepared using 
1% SDS-lysis buffer and boiling which efficiently solubilizes chromatin-associated proteins 
(Figure 6C). Immunoblotting using the anti-UbTET2(K1299) antibody detected one band in 
SDS-lysate, but not in NP40-lysate, that corresponds in size to the upper band detected by 
the TET2 antibody, further supporting the presence of K1299-ubiquitylated TET2 presents 
predominantly in the NP40-insoluble, nuclear fraction. To directly demonstrate that the 
monoubiquitylated TET2 binds to chromatin, we separated U2OS whole cell extracts made 
from a non-ionic detergent (0.1% Triton X-100) lysis buffer into six fractions and 
determined the distribution of TET2 by direct immunoblotting using anti-TET2 antibody 
(Figure 6D). We found that upper monoubiquitylated TET2 is present almost exclusively in 
the chromatin-enriched fraction (P3) and was hardly detectable in the cytosolic (S1, S2 and 
P2) or soluble nuclear fractions (S3). A very small amount of lower, unmodified TET2 was 
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also detected in the chromatin fraction. The same assay was repeated using the lysate 
derived from U2OS cells overexpressing K1299N mutant TET2. It was found that the lower, 
unmodified band of TET2K1299N, like that wild-type TET2, was not detected in the cytosolic 
(S1, S2 and P2), but unlike the wild-type TET2, the ubiquitylation-deficient TET2K1299N 
was not detected in the chromatin-enriched fraction (Figure 6E). Collectively, these results 
demonstrate that VprBP promotes TET2 protein binding to DNA and that this binding 
requires the monoubiquitylation at Lys1299.
Oncogenic TET2 mutations disrupt VprBP regulation
To directly test whether monoubiquitylation is critical for TET function in vivo, the CD 
domain and full length of three murine TET proteins that harbor mutations at the 
ubiquitylation site—Tet1 (K1537N, K1537E); Tet2 (K1212N, K1212E); and Tet3 (K983N, 
K983E)—were ectopically expressed. TET activity was examined in vivo by 
immunofluorescence using 5hmC antibody. Both wild-type and mutant TET proteins were 
expressed at similar levels (Figure S5A) and mutation of the monoubiquitylation site did not 
disrupt binding between the TET proteins and VprBP (Figure S5B). Both K1212E and 
K1212N (corresponding to K1299E and K1299N in human TET2) mutations targeting the 
monoubiquitylation site in mouse Tet2 abolished Tet2’s activity in catalyzing 5hmC 
production in cells, whether assayed using full length protein (Figure 7A) or CD domain 
(Figure S5C). Dot-blot assay using the genomic DNA isolated from transfected cells 
confirm that both K1212E and K1212N mutants failed to produce 5hmC in vivo (Figure 
S5D), which also applied to both Tet1 and Tet3. Regardless of assaying using the full length 
and CD domain, mutations targeting the monoubiquitylation site in either Tet1 (Figure S5E) 
or Tet3 (Figure S5F) also abolished the function of these two Tet enzymes in producing 
5hmC in cells under immunofluorescence. Dot-blot assay of genomic DNA further 
confirmed the loss of activity in producing 5hmC in cells by both mutant Tet1 and Tet3 with 
disrupted monoubiquitylation site (Figure S5D). These results indicate that VprBP binding 
to TET proteins per se is not sufficient for TET activity, but rather monoubiquitylation is 
critical for TET activity (see Discussion). Mutation of Lys983 to either Glu (K983E) or Asn 
(K983N) in both the CD domain and full length Tet3, but not in Tet1 or Tet2, also altered 
Tet3’s almost exclusive nuclear localization to one that is mostly cytoplasmic. Whether 
monoubiquitylation selectively regulates the subcellular localization of TET3 has not been 
determined.
TET2 gene is frequently mutated in hematopoietic malignancies. More than half of the 
mutations result in protein truncation, indicating that loss-of-function is responsible for 
pathogenesis. In addition, several hundred nonsynonymous point mutations have been 
reported, but only a few that disrupt the binding of TET2 with either α-KG or Fe2+ have 
been functionally characterized (Ko et al., 2010). Given our finding that two different AML 
mutations targeting the K1299 monoubiquitylation site of TET2 inactivate its activity in 
vivo, we hypothesized that additional mutation(s) may disrupt both CRL4VprBP-mediated 
TET2 monoubiquitylation and TET2 activity. A number of AML-derived point mutations 
surrounding K1299 at the homologous site in mouse Tet2 were created, and their 
ubiquitylation was determined. Several mutations, in addition to K1299N and K1299E, were 
found to abolish Tet2 ubiquitylation, including C1298Y, F1300S, and R1302G 
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(corresponding to C1211Y, F1213S and R1215G in mouse Tet2) (Figure 7B), which has 
been reported in three, two, and two independent cases of human AML, respectively. 
Binding analysis revealed that F1213S and R1215G disrupted TET2 binding to VprBP 
(Figure 7C), providing an explanation of how mutations target these two residues disrupt 
TET2’s monoubiquitylation. However, the C1211Y mutation did not disrupt the 
monoubiquitylation site nor significantly affect VprBP-TET2 binding, suggesting an 
additional step after binding of VprBP to TET2 that is important for CRL4VprBP-mediated 
TET2 monoubiquitylation. Similar to the K1299N and K1299E mutants, ubiquitylation-
deficient C1211Y, F1213S and R1215G mutants all lost their activity in vivo (Figure 7D). In 
vitro assay using two different substrates, methylated double-stranded DNA (dsDNA) 
oligonucleotides (Figure S5G) and total genomic DNA (Figure S5H) demonstrate that 
mutants of TET2 deficient in monoubiquitylation still retain the catalytic activity as 
determined by the decrease of 5mC and accumulation of 5caC. Together, these results 
demonstrate that multiple, recurrent AML-derived mutations in TET2 disrupt CRL4VprBP-
mediated TET2 monoubiquitylation, while not affecting TET2’s catalytic activity, disrupt 
the VprBP-TET2 binding, the monoubiquitylation site, or another undetermined regulatory 
step, leading to functional inactivation of TET2 in vivo (Figure 7E).
DISCUSSION
VprBP is a critical regulator of TET family dioxygenases
While the biological function and biochemical mechanism of TET enzymes have been 
extensively investigated, little is known about their regulation at present. We have shown 
that VprBP is a critical regulator of all three TET enzymes. The importance of VprBP in 
promoting the function of TET is supported by the genetic evidence that conditional 
knockout of Vprbp in oocytes resulted in a loss of TET3 and abolishment of paternal 
chromosome 5-hmC. VprBP’s importance is also supported by the finding that, in leukemia, 
multiple recurrent oncogenic mutations in TET2 disrupt VprBP-mediated TET2 activation.
CRL4VprBP-mediated monoubiquitylation promotes TET binding to DNA
We present compelling evidence in this study that VprBP targets the TET proteins for 
monoubiquitylation by the CRL4VprBP E3 ligase. A lysine residue (K1299 in human TET2), 
which is invariably conserved among all three TET proteins, is identified as the site of 
CRL4VprBP-mediated monoubiquitylation. Mutation of this conserved lysine residue 
abolishes the monoubiquitylation of all three TET proteins. We demonstrated in vivo TET2 
monoubiquitylation using the antibody specifically recognizing K1299-ubiquitylated TET2. 
The abundances of the monoubiquitylated TET2 vary from cell line to cell line, are inhibited 
by a deubiquitinase inhibitor and are increased when cells are stimulated to enter the cell 
cycle or when VprBP is overexpressed. These observations indicate that TET2 
monoubiquitylation is dynamically regulated in cells.
VprBP-mediated monoubiquitylation plays a critical role in TET activation by promoting 
their ability to bind DNA, but not catalytic activity of TET enzyme. As binding to DNA is a 
prerequisite for the function of TET in catalyzing 5mC hydroxylation, our findings provide a 
molecular basis for the activation of TET dioxygenases by VprBP-mediated 
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monoubiquitylation. The exact mechanism by which monoubiquitylation promotes TET 
DNA binding is currently unknown. It is conceivable that conjugation of a ubiquitin could 
disassociate TET from a factor that blocks TET’s binding to DNA, bridge the binding of 
TET with a factor that recruits TET to DNA, or expose a masked DNA binding domain. 
Very recently, the crystal structure of a fragment of human TET2 (residues 1129 to 1936) 
which deleted a large low-complexity region (residues 1481-1843) predicted to be 
unstructured has been resolved in complex with DNA (Hu et al., 2013). Notably, in this 
TET2-DNA complex, the K1299 monoubiquitylation site directly contacts DNA. We 
speculate that monoubiquitylation in TET may directly affect their binding with DNA, for 
example by stabilizing either the conformation of full-length TET2 containing the 
unstructured sequence.
Oncogenic mutations in TET2 disrupt VprBP-mediated regulation
The TET2 gene is frequently mutated in hematopoietic malignancies of both myeloid and 
lymphoid lineages. The results presented in this study reveal a novel mechanism for 
oncogenic inactivation of TET2, by disruption of VprBP-mediated monoubiquitylation. As 
we selectively characterized only a small number of point mutations surrounding the 
ubiquitylation site, the full spectrum of oncogenic mutations targeting VprBP-mediated 
TET2 ubiquitylation is unknown and could be underappreciated. TET genes are not 
frequently mutated in solid tumors. Yet, many different types of malignant tissues have been 
found to contain very low or undetectable levels of 5hmC compared with normal tissues 
[e.g. ref. (Yang et al., 2013)], implicating additional mechanisms for functionally 
inactivating TET. In glioma where mutation of a TET gene has not been reported, TET 
enzymes are catalytically inactivated by the D-2-HG oncometabolite produced by mutated 
IDH1 (Chowdhury et al., 2011; Dang et al., 2009; Xu et al., 2011). The findings reported 
here present an additional target, CRL4VprBP E3 ligase, for oncogenic inactivation of TET 
function. It will be important to explore the expression of VprBP and other CRL4 
components in different types of tumors.
Experimental Procedures
More detailed descriptions for procedures below and additional procedures are provided in 
the Supplemental Information.
Mice and oocytes and zygotes analyses
Wild type C57/B6 mice were from the Zhejiang Academy of Medical Science, China. 
Vprbpflox/flox (McCall et al., 2008) and Zp3-Cre (Lan et al., 2004) were previously 
generated. Animal care and experimental procedures were in accordance with the Animal 
Research Committee guidelines of Zhejiang University. For super-ovulation assay, pubertal 
mice (21-23 days old) were injected intraperitonally (i.p.) with 5 IU of pregnant mare serum 
gonadotrophin (PMSG). After 44 hours, the mice were i.p. injected with 5 IU Human 
chorionic gonadotropin (hCG). After an additional 16 hours, oocyte/cumulus masses were 
surgically removed from oviducts and the numbers of oocytes were counted. To obtain 
fertilized eggs (zygotes), female mice were mated. Zygotes were harvested from oviducts at 
20 hours after hCG injection and used for confocal microscopy and real-time PCR analyses.
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Electrophoretic mobility shift assay
Biotin labeled single-stranded oligonucleotides used for TET-DNA binding assay were 
synthesized and annealed. 500 ng of immunopurified Flag-TET2 was incubated in a total 20 
ul reaction mixture containing 1 ng of biotin labeled oligonucleotide. The resulting protein-
DNA complexes were resolved in a 6% DNA retardation gel in 0.5 × TBE buffer, 
transferred to a nylon membrane and blotted with streptavidin-HRP. The gel-shift assays 
were performed using the LightShift Chemiluminescent EMSA Kit.
Cell fractionation
4×107 U2OS cells were harvested and lysed by Triton X-100. Nuclei were collected in pellet 
1 (fraction P1) by low-speed centrifugation (5 min, 1,300g, 4°C). The supernatant (S1) was 
further clarified by high-speed centrifugation (10 min, 15,000g, 4°C) to remove cell debris 
and insoluble aggregates (P2). Nuclei were washed once in buffer A, and then lysed. 
Insoluble chromatin (P3) was collected by centrifugation (5 min, 1,700g, 4°C), washed once 
in buffer B, and centrifuged again under the same conditions. The resulting six fractions 
were re-suspended in the Laemmli buffer, boiled for 15min and resolved by SDS-PAGE for 
western analysis.
In vitro TET2 activity assay
In vitro assay of TET2 catalytic activity was performed using two different substrates, 
methylated dsDNA oligonucleotides and total genomic DNA. To prepare the TET enzyme, 
Flag-tagged wild-type and AML-derived full length TET2 mutants were ectopically 
expressed in HEK293T cells, immunoprecipitated, and eluted by Flag peptide. The reactions 
were carried out as described in detail in the Supplemental Information, denatured and then 
neutralized. The reaction mixtures were spotted on nitrocellulose membrane, cross linked 
and incubated overnight with antibodies recognizing 5mC, 5hmC antibody, 5fC antibody, or 
5caC, followed by chemiluminescence.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. VprBP binds to TET family proteins
(A) Top, Domain structure of human VprBP. Bottom, 293T cells were transiently 
transfected with expression vectors for FLAG-TET2 and a series of HA-VprBP fragments. 
Cell lysates were subjected to IP with an HA antibody, followed by Western blot (WB).
(B) Top, Domain structure of mouse TET2. Bottom, 293T cells were transiently transfected 
with expression vectors for a series of FLAG-TET2 fragments. Cell lysates were subjected 
to IP with FLAG antibody, followed by WB. CD: cysteine-rich, dioxygenase domain.
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(C) FLAG-tagged mouse TET CD domains were immunoprecipitated from 293T cells and 
their associated proteins were detected by WB. CD1, CD2 and CD3 refer to the CD domain 
of mouse TET1 (residue 1400 to 2039, NP_001240786.1), TET2 (residue 1042 to 1912, 
NP_081660.1) and TET3 (residue 697 to 1668, NP_898961.2), respectively. CM: catalytic 
mutant (H1620Y/D1622A for mouse TET1, H1295Y/D1297A for mouse TET2).
(D) FLAG-TET proteins were immunoprecipitated from 293T cells and their associated 
proteins were detected by WB.
(E) Endogenous VprBP was immunoprecipitated from MEF, mouse ES cells and human 
monocytes and its association with TET proteins was determined by WB.
(F) Recombinant FLAG-TET2-CD was incubated with recombinant His6-VprBP or GST-
DDB1. Binding was monitored by WB.
See also Figure S1 and Table S1, S2.
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Figure 2. VprBP is essential for TET activity
(A) VprBPf/f MEFs were infected with adenovirus expressing Cre. mRNA level was 
analyzed by quantitative RT-PCR and 5mC and 5hmC level was analyzed by dot blot.
(B) Female Vprbpf/f and Vprbpf/f;Zp3-Cre mice were superovulated with PMSG and hCG 
before mating to wild-type males. Successful mating was confirmed by the presence of 
vaginal plugs. 48 hours after hCG, embryos were obtained from the oviducts and examined 
microscopically.
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(C) The expression of VprBP in VprBPf/f or VprBPf/f;Zp3-Cre oocytes from the germinal 
vesicle (GV) stage was examined by immunofluorescence. (D, E) The expression of Tet3 
(B), 5mC and 5hmC (C) in VprBPf/f or VprBPf/f;Zp3-Cre oocyte-derived zygotes were 
examined by immunofluorescence. (F) The expression of VprBP and Tet3 mRNA in 
VprBPf/f or VprBPf/f;Zp3-Cre oocytes from germinal vesicle (GV) stage was determined by 
quantitative RT-PCR analysis.
See also Figure S2 and Table S2, S3.
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Figure 3. CRL4VprBP monoubiquitylates TET proteins
(A) 293T cells transfected with plasmids of Myc-VprBP, FLAG-TET2, and HA-ubiquitin 
were lysed and subjected to IP with an antibody to FLAG under denaturing conditions (0.1% 
SDS). The resulting precipitates were blotted with the indicated antibodies.
(B) 293T cells were transfected with plasmids of HA-ubiquitin along with siRNA for 
VprBP, DDB1, or CUL4 and subsequently lysed and subjected to IP with an antibody to 
TET2 under denaturing conditions. Precipitates were immunoblotted.
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(C) 293T cells transfected with a plasmid of HA-ubiquitin along with siRNA for CUL4A, 
CUL4B or CUL4A and CUL4B were lysed and subjected to IP with an antibody to TET2 
under denaturing conditions. Precipitates were blotted.
(D) In vivo ubiquitylations of ectopically expressed TET1 and TET3 proteins were 
determined in cells transfected with siRNA targeting VprBP.
(E) In vivo ubiquitylations of ectopically expressed TET1 and TET3 proteins were 
determined in cells with or without co-expression of VprBP.
(F) Recombinant FLAG-TET2 was incubated with different combinations of E1, E2, and 
CRL4AVprBP (E3) along with ATP and ubiquitin, followed by IP with a FLAG antibody. 
Ubiquitylated TET2 was examined by WB with anti-ubiquitin.
(G) Recombinant FLAG-TET2 was incubated with ubiquitin, E1, E2, CRL4A along with 
different combinations of VprBP mutants, followed by IP with a FLAG antibody.
See also Figure S3, Table S2.
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Figure 4. CRL4VprBP ubiquitylates TET proteins on a conserved Lys residue
(A) Sequence alignment of TET2 surrounding K1299 from various vertebrate species, 
including human (H. sapiens, NCBI reference number: NP_001120680.1), mouse (M. 
musculus, NP_001035490), chicken (G. gallus, NP_001264723), lizard (A. carolinensis, 
XP_003226445.1), frog (X. laevis, ADU77105), and zebrafish (D. rerio, XP_005168673).
(B) Sequence alignment of the human and mouse TET proteins surrounding human TET2-
K1299, including human TET1 (NP_085128.2), TET2 (NP_001120680.1), TET3 
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(NP_659430.1), mouse TET1 (NP_081660), TET2 (NP_001035490.2) and TET3 
(ADR57138.1).
(C, D). Ubiquitylation of the CD domain (C) and full length (D) mouse TET proteins were 
determined in 293T cells transfected with plasmids expressing HA-ubiquitin, WT TET2, 
AML-derived K1299 mutant TET2, or the corresponding AML-derived TET1 and TET3 
mutants. Cells were lysed and subjected to IP with a FLAG antibody under denaturing 
conditions. Precipitates were blotted.
(E) 293T cells were transfected with a plasmid expressing the FLAG-tagged human TET2 
CD domain and Myc-VprBP as indicated. Total protein lysates were separated on a 7% 
SDS-PAGE and blotted.
(F) 293T cells were co-transfected with plasmids expressing Myc-VprBP and FLAG-tagged 
WT or mutant TET2 CD domains as indicated. Total protein lysates were separated on a 7% 
SDS-PAGE and blotted. KE: K1299E; KN: K1299N, KR: K1299R.
(G) 293T cells were transfected with plasmid expressing indicated WT or ubiquitylation site 
mutant (KN) human TET2 protein. Cells were lysed in SDS (1%) buffer, diluted for 10 fold 
and subjected to IP with Flag beads under denaturing conditions. Precipitates were blotted 
with Flag and UbTET2 (K1299) antibodies.
(H) Total protein extracts were prepared from indicated cell lines using a SDS (1%) lysis 
buffer and revolved through a gradient (4-15%) SDS-PAGE, and blotted with either TET2 
and UbTET2(K1299) antibody.
(I) U2OS cells were serum deprived for 24h followed by FBS stimulation according to the 
indicated time course. The cells were then lysed with 1% SDS buffer and blotted with TET2 
and UbTET2(K1299) antibody. The relative amount of monoubiquitylated TET2 was 
determined by normalization to unmodified TET2.
(J) U2OS cells were treated with 8 μM PR619 for 24h, lysed with 1%SDS buffer, and 
blotted with TET2 and UbTET2(K1299) antibody.
See also Figure S4, Table S2.
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Figure 5. VprBP-mediated monoubiquitylation promotes TET binding to DNA in vitro
(A) 293T cells were transfected with a plasmid expressing FLAG-tagged WT or AML-
derived mutant TET2 as indicated. TET2 proteins were immunopurified and incubated with 
double-stranded DNA oligonucleotides containing a single unmethylated or methylated 
CpG. Protein-DNA binding was determined by gel-shift assay. Protein levels were analyzed 
by WB.
(B) 293T cells were transfected with a plasmid expressing FLAG-tagged WT or mutant 
TET1 or TET3 as indicated. Proteins were immunopurified from 293T cells and incubated 
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with double-stranded DNA oligonucleotides containing a single unmethylated CpG. Protein-
DNA binding was determined by gel-shift assay. Protein levels were analyzed by WB.
(C) 293T cells were transfected either alone with plasmids expressing FLAG-tagged WT or 
mutant TET2, or co-transfected with HA-VprBP as indicated. Proteins were immunopurified 
from 293T cells and incubated with DNA oligonucleotides containing a single unmethylated 
CpG. Protein-DNA binding was determined by gel-shift assay. Protein levels were analyzed 
by WB.
(D) 293T cells were triply transfected with FLAG-TET2, Myc-VprBP and HA-Ub. 
Sequential immunopurification was performed: first using the antibody to FLAG to purify 
TET2 protein and then the antibody to HA to enrich ubiquitylated TET2. DNA binding 
activity of proteins eluted from FLAG beads or HA beads was determined by gel-shift assay. 
Protein and ubiquitylation levels were analyzed by WB.
(E) 293T cells were triply transfected with FLAG-TET2, Myc-VprBP and HA-Ub. 
Immunopurification and immunodepletion was performed: first using the antibody to FLAG 
to purify TET2 protein and then the antibody to HA to deplete ubiquitylated TET2. DNA 
binding activity of proteins before or after HA depletion was determined by gel-shift assay. 
Protein and ubiquitylation levels were analyzed by WB.
See also Table S2.
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Figure 6. VprBP-mediated monoubiquitylation promotes TET binding to DNA in vivo
(A) 293T cells were transfected with plasmid DNA encoding FLAG-tagged WT or lysine 
mutants of TET2. DNA/protein complexes were cross-linked and subjected to ChIP analysis 
with a FLAG antibody. Immunoprecipitates were analyzed by quantitative PCR (qPCR) 
with primers for the indicated TET2 target gene promoters. The signal intensity on the y 
axes represents the fold enrichment of DNA amplified by qPCR from cells expressing TET2 
compared with that from mock cells transfected with empty vector. See Table S4 for primer 
sequences.
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(B) 293T cells were transfected with plasmid DNAs expressing FLAG-tagged TET2 and 
WT or mutant VprBP proteins as indicated. ChIP-qPCR analyses were performed as in 
Figure 6A. The signal intensity on the y axes represents the fold enrichment of DNA 
amplified by qPCR from cells expressing TET2 compared with that from mock cells 
transfected with empty vector. See Table S4 for primer sequences.
(C) U2OS cells were lysed with 0.5% NP40 or 1% SDS buffer, followed by WB with TET2 
and UbTET2(K1299) antibody, respectively.
(D) U2OS cells were lysed in a non-ionic (0.1% Triton X-100) lysis buffer and lysates were 
separated into six fractions, followed by WB.
(E) U2OS cells were transfected with a plasmid expressing K1299N mutant TET2 and then 
lysed, fractionated and blotted as Figure 6D.
See also Table S2, S4.
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Figure 7. Multiple recurrent leukemia-derived mutations in TET2 disrupt VprBP-mediated 
TET2 monoubiquitylation
(A) U2OS cells were transiently transfected with an expression vector for FLAG-TET2 or 
the TET2 lysine mutant, and the cells were fixed and immunostained with anti-FLAG (red) 
and anti-5hmC (green) antibodies. The nucleus was visualized by DAPI. Scale bar, 10 μm.
(B) The in vivo ubiquitylation level of TET2 leukemia mutants was examined by IP 
followed by WB.
(C) Binding of TET2 leukemia mutants to VprBP was examined by IP followed by WB.
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(D) Activity of TET2 leukemia mutants was examined by immunofluorescence. See Figure 
S5D for the dot-blot assay and also Figure S5E and S5F for the similar assays of Tet1 and 
Tet3 mutants. Also see Figure S5G and S5H for the in vitro assay of the catalytic activity of 
WT and tumor-derived TET2 mutants.
(E) Summary of ubiquitylation level, VprBP binding, in vivo and in vitro activity of TET2 
leukemia mutants.
See also Figure S5, Table S2.
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